Doruk et al. [43] found that patients with GDM had a 4.6 relative risk of adverse events during pregnancy and that adiponectin levels at 24–28 weeks were statistically significantly lower in patients with adverse events taken as a whole. This evidence concerns the gene ADIPOQ and gestational diabetes.